The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.
6,6-Fused heterocyclic ureas as highly potent TRPV1 antagonists
作者:Wei Sun、Hyo-Shin Kim、Sunho Lee、Aeran Jung、Sung-Eun Kim、Jihyae Ann、Suyoung Yoon、Sun Choi、Jin Hee Lee、Peter M. Blumberg、Robert Frank-Foltyn、Gregor Bahrenberg、Klaus Schiene、Hannelore Stockhausen、Thomas Christoph、Sven Frormann、Jeewoo Lee
DOI:10.1016/j.bmcl.2014.12.086
日期:2015.2
A series of N-[2-(4-methylpiperidin-1-yl)-6-(trifluoromethyl)-pyridin-3-yl}methyl] N'-(6,6-fused heterocyclic) ureas have been investigated as hTRPV1 antagonists. Among them, compound 15 showed highly potent TRPV1 antagonism to capsaicin, with K-i(ant) = 0.2 nM, as well as antagonism to other activators, and it was efficacious in a pain model. A docking study of 15 with our hTRPV1 homology model indicates that there is crucial hydrogen bonding between the ring nitrogen and the receptor, contributing to its potency. (C) 2015 Elsevier Ltd. All rights reserved.
LISITSYN V. N.; BOROVKOV A. G., TR. MOSK. XIM.-TEXNOL. IN-T,(1986) N 141, 14-26